Photobiomodulation in the treatment of patients with non-center-involving diabetic macular oedema
Tang J, Herda AA, Kern TS
The British journal of ophthalmology · 57 citas
Cómo se estudió
- Diseño
- Estudio de casos y controles (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Eye Institute
- Gobierno
- NEI NIH HHS
- Subvenciones
- National Eye Institute (R01EY022938); National Eye Institute (R01 EY000300); National Eye Institute (R01EY00300)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2014-03-28 · Br J Ophthalmol · vol. 98 · número 8 · págs. 1013–1015
- Editorial
- BMJ
- Citado
- 77 citas · más que el 95% de estudios similares · 4.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 8 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Laser Applications in Dentistry and Medicine · Retinal Diseases and Treatments · Dermatologic Treatments and Research
- Palabras clave
- Medicine, Diabetic retinopathy, Diabetes mellitus, Visual acuity, Adverse effect, Ophthalmology, Retinal, Retinopathy, Surgery, Internal medicine
- MeSH
- humans, diabetic retinopathy, phototherapy, case-control studies, adult, aged, middle aged, point-of-care systems, male, macular edema
3 autores
- Johnny Cheuk On Tang🇺🇸 · autor de correspondenciaLouis Stokes Cleveland VA Medical Center
- Ashley A. Herda🇺🇸University of Kansas Medical Center
- Timothy S. Kern🇺🇸Louis Stokes Cleveland VA Medical Center; University School; Case Western Reserve University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Far-red/near-infrared phototherapy or photobiomodulation (PBM) has recently been reported to be an effective and non-invasive treatment method to inhibit lesions of diabetic retinopathy (DR) in animals. This study investigated the safety and efficacy of PBM in diabetic patients to treat non-center-involving diabetic macular oedema (NCDME).
Methods
This was a non-randomised, consecutive, case series, where 4 patients with type 2 diabetes with NCDME were treated for 160 s per day with PBM for 2-9 months. Demographic data including age, sex, HbA1c%, electronic ETDRS visual acuity, and retinal and macular thickness were measured using spectral domain ocular coherence tomography (SD-OCT) before and after treatment.
Results
Four eyes of 4 patients were treated, with fellow eyes serving as untreated controls. Daily PBM treatment for only 80 s per treatment twice daily caused a significant reduction in focal retinal thickening in all 4 treated eyes. No adverse effects attributable to therapy were noted by the patients or study investigators during the study period.
Conclusions
PBM potentially offers a non-invasive and cost-effective therapeutic option for patients with NCDME. Further studies of this therapeutic option in DR are warranted.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.